Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
SAN DIEGO, Oct. 16, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CRNX) today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024 after the market closes. Company management will host a conference call at 4:30 p.m. ET to discuss financial results and provide a business update.
Conference Call & Webcast
| Tuesday, November 12 @ 4:30 p.m. ET | ||
| Domestic: | 1-800-579-2543 | |
| International: | 1-785-424-1789 | |
| Conference ID: | CRNXQ3 | |
Participants can use the dial-in numbers above OR access the call via live webcast on the of the Crinetics website. To ensure a timely connection, it is recommended that participants dial-in or register at least 15 minutes prior to the scheduled start of the call.
The webcast will be archived on the Investor Relations section of .
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics’ lead development candidate, paltusotine, is the first investigational once-daily, oral, selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide agonist that has completed Phase 3 clinical development for acromegaly and is in Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant (CRN04894), an investigational, first-in-class, oral ACTH antagonist, that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications.
Investors:
Gayathri Diwakar
Head of Investor Relations
(858) 345-6340
Media:
Natalie Badillo
Head of Corporate Communications
(858) 345-6075
